Nobutaka Ida
Toray Industries
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nobutaka Ida.
Cancer Chemotherapy and Pharmacology | 1982
Tateshi Kataoka; Fujiko Oh-hashi; Yoshio Sakurai; Nobutaka Ida
SummaryWe compared the in vitro antiproliferative activity of highly purified interferon (IFN)-β (>107 U protein/mg in antiviral activity) with that of IFNs-α and lymphoblastoid, using human cells of malignant and non-malignant origin. IFN-β was the least active of three IFNs in suppressing Daudi cell proliferation. Three hematological cells other than Daudi cells cultivated in suspension were insensitive to each of three IFNs. IFN-β was more active than IFNs-α and lymphoblastoid in suppressing all eight epithelioid cells tested and, particularly with respect to five epithelioid cells sensitive to IFN, IFN-β was seven to 49 times as active as IFN-α. These results indicate that suppression of cell proliferation by IFN depends not only on the target cell species but also on the IFN species, and emphasize the need for careful selection of the most appropriate IFN species in therapy.We found that the antiproliferative characteristics of the present IFN-β preparation were consistent with those reported previously, supporting the idea that IFN-β molecules in the present preparation were responsible for suppressing cell proliferation. The antiproliferation activity of our preparation was species-specific but not selective for cells of malignant origin; it was absorbable by IFN-sensitive but not by IFN-insensitive cells; and it was achieved by a cytostatic effect.
Prostaglandins Leukotrienes and Essential Fatty Acids | 2009
Masahiko Takenaka; Noboru Machida; Nobutaka Ida; Nahoko Satoh; Hajimu Kurumatani; Yoshihisa Yamane
Unilateral ureteral obstruction (UUO) is a representative model for investigating the common mechanism of decreasing renal function in chronic renal failure. In this study, we present a new partial UUO model in adult rats and evaluated the effect of beraprost sodium (BPS: stable prostaglandin I(2) (PGI(2)) analog). We could make reproductive and uniform partial UUO by ligating the left ureter together with a 0.5 mm diameter stainless steel wire with nylon thread, and withdrawing the stainless wire. One week later, the ureteral obstruction was released. After 3 weeks from the release of UUO, all animals of control group, without BPS administration, developed basophilic degeneration of tubular epithelium, tubular dilatation and interstitial fibrosis. The areas of tubular degeneration and fibrosis were significantly reduced in the BPS group, orally administered BPS 300 microg/kg twice a day from the next day of the release of obstruction, than in control group. In conclusion, we can established the adult rat partial UUO-release model and revealed that BPS can inhibit renal tubular damage and tubulointerstitial fibrosis.
Cancer Letters | 1994
Ken-ichi Yoshizawa; Tasuku Okamoto; Keiko Moriya; Akiko Izawa; Yu-Ichiro Satoh; Masanobu Naruto; Nobutaka Ida
The growth of inoculated colon 26 adenocarcinoma (colon 26) in mice gradually increased the platelet count owing to murine IL-6 secreted from the tumor, while Lewis lung carcinoma (LLC) decreased the platelet count in the hosts, depending on the tumor growth. Natural human IL-6 injections (hIL-6), 280 micrograms/kg/day, stimulated the platelet production in both types of carcinoma-bearing mice. When the administration of mitomycin C or cisplatin decreased the platelet number as a side reaction with a concomitant of suppressing the growth of colon 26 and LLC, respectively, hIL-6 could also increase the platelet count without the augmentation of tumor growth. However, loss of carcass weight was observed in colon 26-bearing mice treated with hIL-6, suggesting the development of cachexia is associated with hIL-6 administration. Despite the possibility of inducing cachexia in some types of tumors, our results suggest that IL-6 could be a useful means of restoring the decreased platelet number in cancer patients after intensive chemotherapy.
Archive | 1995
Masayuki Miyata; Reiji Kasukawa; Masanobu Naruto; Nobutaka Ida; Yu-Ichiro Sato; Katsuaki Kojima; Nobuo Ida
Journal of Interferon and Cytokine Research | 1996
Ken-ichi Yoshizawa; Masanobu Naruto; Nobutaka Ida
Journal of interferon research | 1984
Yu-Ichiro Satoh; Kyoko Kasama; Akemi Kajita; Hirohiko Shimizu; Nobutaka Ida
Journal of Veterinary Medical Science | 2007
Tatsuo Kaneshige; Yuuto Saida; Ryou Tanaka; Aiko Soda; Akiko Fukushima; Nobutaka Ida; Masahiko Takenaka; Yoshihisa Yamane
Cancer Research | 1984
Tateshi Kataoka; Fujiko Oh-hashi; Yoshio Sakurai; Kazue Usuki; Nobutaka Ida
Archive | 1995
Nobuo Ida; Nobutaka Ida; Reiji Kasukawa; Katsuaki Kojima; Masayuki Miyata; Masanobu Naruto; Yu-Ichiro Sato
Chemical & Pharmaceutical Bulletin | 1987
Kiyomi Kakiuchi; Masaki Ue; Mitsunori Takeda; Toshihiro Tadaki; Yuji Kato; Teruhisa Nagashima; Yoshito Tobe; Hiroshi Koike; Nobutaka Ida; Yoshinobu Odaira